• About
  • Contact
Tuesday, May 20, 2025
No Result
View All Result
Londoner News
  • Home
  • London
  • Britain
  • Europe
  • America
  • International
  • Submit Article
  • Other
    • Health
    • Tech
    • Travel
    • Science
  • Home
  • London
  • Britain
  • Europe
  • America
  • International
  • Submit Article
  • Other
    • Health
    • Tech
    • Travel
    • Science
No Result
View All Result
Londoner News
No Result
View All Result
Home Britain

Tiziana Life delighted with data from liver cancer treatment trials in Italy

by The Editor
May 15, 2020
in Britain
0
Tiziana Life delighted with data from liver cancer treatment trials in Italy
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Tiziana Life Sciences (LON:TILS NASDAQ:TLSA) has received encouraging clinical trial data for its liver cancer treatment Milciclib from two clinical trials in Italy.

Two online abstracts from the studies were published at the virtual annual meeting of the American Society of Clinical Oncology 2020 (ASCO20).

A Phase 2a clinical trial with orally administered Milciclib in sorafenib-resistant hepatocellular carcinoma (HCC) patients met the primary endpoint of being well tolerated with manageable toxicities and no recorded drug-related deaths.

The secondary endpoint of clinical activity was also met with five patients taking the treatment for more than nine months for compassionate reasons.

“Results from the phase 2a clinical study demonstrating clinical activity in these advance cases of HCC are notable,” stated Prof. Angelo Sangiovanni, the principal investigator of the study at the prestigious Granda Ospedale Maggiore Policlinico in Milan.

“The fact that many of the treated patients continued with the treatment, even after completing 6 months duration of the study, is particularly very impressive.”

The second abstract reported preliminary clinical data from an ongoing investigator-originated trial of seven patients with a combination of orally administered Milciclib and Regorafenib in liver transplant patients with recurrent HCC.

Thus far, the sRead More – Source

[contf]
[contfnew]

Proactiveinvestors

[contfnewc]
[contfnewc]

The Editor

Next Post
FTSE 100 tanks as traders fear protracted downturn

FTSE 100 tanks as traders fear protracted downturn

Recommended

Market Now: Over 90 stocks hit fresh 52-week lows on NSE

Market Now: Over 90 stocks hit fresh 52-week lows on NSE

7 years ago

Virgin Atlantic sale: Airline launches HUGE discount on return flights to the US

6 years ago

Popular News

    Connect with us

    About Us

    We bring you the best Premium WordPress Themes that perfect for news, magazine, personal blog, etc. Check our landing page for details.

    Category

    • America
    • Britain
    • Entertainment
    • Europe
    • Health
    • International
    • latest news
    • London
    • Markets
    • Science
    • Tech
    • Travel
    • Uncategorized
    • Women

    Site Links

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • About
    • Contact

    © 2020 londonernews

    No Result
    View All Result
    • Home
    • Science
    • Travel
    • Tech
    • Health

    © 2020 londonernews